
    
      This is a multi-center, multi-cohort, open-label phase 2 clinical study to evaluate the
      anti-tumor activity, safety, PK profile, immunogenicity and potential biomarkers of AK104
      alone or in combination with for the treatment of advanced hepatocellular carcinoma
    
  